がん腫瘍プロファイリング市場規模、シェア、成長分析、がんタイプ別、バイオマーカータイプ別、技術別、手法別、用途別、地域別 - 産業予測、2025-2032年

がん腫瘍プロファイリングの世界市場規模は、2023年に121億米ドルと評価され、2024年の134億4,000万米ドルから2032年には312億米ドルに成長し、予測期間（2025-2032年）のCAGRは11.1％で成長する見通しです。

世界のがん検出・治療市場は、がん有病率の上昇と腫瘍プロファイリングにおけるバイオマーカーの利用増加によって強化されています。研究資金の充実と技術の進歩が、がんおよび腫瘍プロファイリング分野の成長を後押ししています。さらに、個別化医療とポイントオブケア診断に向けた動向は、市場参入企業にとって今後数年間で大きなビジネスチャンスを生み出すと予想されます。COVID-19のパンデミックは当初、がん検査・診断に混乱をもたらしましたが、市場全体は回復力を維持しました。予測期間中、ゲノミクス、プロテオミクス、エピジェネティクス、メタボロミクスを含むがん／腫瘍プロファイリング分野は成長すると予想され、中でもゲノミクスはCAGR 19.7%と最も高くなると予測され、がんの回復力と進行に関連する遺伝子異常の解明におけるイノベーションを促進します。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

がん腫瘍プロファイリング市場規模：がんタイプ別

• 市場概要
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• メラノーマがん
• その他のがん

がん腫瘍プロファイリング市場規模：バイオマーカータイプ別

• 市場概要
• ゲノムバイオマーカー
• タンパク質バイオマーカー

がん腫瘍プロファイリング市場規模：技術別

• 市場概要
• 免疫測定
• 次世代シーケンシング
• ポリメラーゼ連鎖反応
• 質量分析
• インサイチューハイブリダイゼーション
• マイクロアレイ
• その他

がん腫瘍プロファイリング市場規模：手法別

• 市場概要
• ゲノミクス
• プロテオミクス
• メタボロミクス
• エピジェネティクス

がん腫瘍プロファイリング市場規模：用途別

• 市場概要
• 調査
• バイオマーカー探索
• 個別化医療
• 臨床応用
• 診断
• 予測
• スクリーニング
• 治療とモニタリング

がん腫瘍プロファイリング市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Illumina, Inc.（USA）
• QIAGEN N.V.（Netherlands）
• NeoGenomics, Inc.（USA）
• Thermo Fisher Scientific（USA）
• Roche Diagnostics（Switzerland）
• Guardant Health, Inc.（USA）
• Foundation Medicine, Inc.（USA）
• Sysmex Corporation（Japan）
• Becton, Dickinson and Company（BD）（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（USA）
• Johnson & Johnson（USA）
• Danaher Corporation（USA）
• Abbott Laboratories（USA）

結論と提言

Global Cancer Tumor Profiling Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.44 billion in 2024 to USD 31.2 billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).

The global cancer detection and treatment market is bolstered by the rising prevalence of cancer and the increasing utilization of biomarkers in tumor profiling. Enhanced research funding and technological advancements are fueling growth in the cancer and tumor profiling sectors. Furthermore, the trend towards personalized medicine and point-of-care diagnostics is anticipated to create substantial opportunities for market participants in the coming years. While the COVID-19 pandemic initially disrupted cancer testing and diagnosis, the overall market remained resilient. During the forecast period, cancer/tumor profiling segments encompassing genomics, proteomics, epigenetics, and metabolomics are expected to thrive, with genomics projected to achieve the highest CAGR of 19.7%, driving innovations in understanding gene abnormalities connected to cancer resilience and progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Tumor Profiling market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Tumor Profiling Market Segments Analysis

Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Tumor Profiling Market

The rise in cancer cases significantly drives the growth of the global cancer tumor profiling market. This increase in cancer prevalence is influenced by several factors, including an aging population, population growth, and shifts in the incidence of various cancer-causing elements. As cancer remains a complex and pervasive disease with various underlying causes, the growing burden necessitates advanced profiling techniques to enhance diagnosis, treatment, and patient outcomes. The urgent need for tailored therapeutic approaches arises from this complex landscape, solidifying the importance of cancer tumor profiling in addressing the ongoing challenges posed by the escalating incidence of cancer worldwide.

Restraints in the Global Cancer Tumor Profiling Market

Challenges related to technical issues in sample collection and storage present significant obstacles to the growth of the global cancer tumor profiling market. While personalized medicine is rapidly evolving and transforming disease identification, classification, and treatment in healthcare, these advancements are hampered by inconsistent sample management processes. As this more tailored approach to treatment becomes integrated into standard clinical practices, its impact on oncology is undeniable. However, the risks associated with sample handling and storage could impede the progress and acceptance of these innovations, ultimately affecting the overall development of the cancer tumor profiling sector.

Market Trends of the Global Cancer Tumor Profiling Market

The Global Cancer Tumor Profiling market is witnessing a significant trend driven by the integration of omics data and advancements in liquid biopsy technologies, projected to exhibit the highest CAGR during the forecast period. This shift aligns with the rising prominence of personalized medicine, transforming disease diagnosis, classification, and treatment. As tailored therapies become a standard in clinical practice, particularly within oncology, the market is evolving to accommodate innovative diagnostic tools and targeted treatment approaches. The convergence of advanced analytics and molecular profiling is revolutionizing cancer care, fostering early detection and improved patient outcomes across the globe.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Tumor Profiling Market Size by Cancer type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer

Global Cancer Tumor Profiling Market Size by Biomarker type & CAGR (2025-2032)

• Market Overview
• Genomic Biomarker
• Protein Biomarker

Global Cancer Tumor Profiling Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunoassays
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Mass Spectrometry
• In-Situ Hybridization
• Microarrays
• Others

Global Cancer Tumor Profiling Market Size by Technique & CAGR (2025-2032)

• Market Overview
• Genomics
• Proteomics
• Metabolomics
• Epigenetics

Global Cancer Tumor Profiling Market Size by Application & CAGR (2025-2032)

• Market Overview
• Research
• Biomarker Discovery
• Personalized Medicine
• Clinical Application
• Diagnostics
• Prognostics
• Screening
• Treatment and Monitoring

Global Cancer Tumor Profiling Market Size & CAGR (2025-2032)

• North America (Cancer type, Biomarker type, Technology, Technique, Application)
  • US
  • Canada
• Europe (Cancer type, Biomarker type, Technology, Technique, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer type, Biomarker type, Technology, Technique, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer type, Biomarker type, Technology, Technique, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer type, Biomarker type, Technology, Technique, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations